Quick Answer
Ernexa Therapeutics Inc. reported Net Income Loss of -$14.08 million for the year ending 2025.
- Ernexa Therapeutics Inc. showed an increase of +68.4% in Net Income Loss from 2024 to 2025.
- This data is from Ernexa Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Ernexa Therapeutics Inc.'s Net Income Loss has declined by 3,421.0%.
- Historical annual values: Fiscal year 2025: -$14.08 million | Fiscal year 2024: -$44.54 million | Fiscal year 2023: -$21.67 million | Fiscal year 2022: -$24.58 million | Fiscal year 2021: -$122.55 million | Fiscal year 2020: -$26.53 million | Fiscal year 2019: -$2.05 million | Fiscal year 2018: -$259.0 thousand | Fiscal year 2017: -$1.08 million | Fiscal year 2016: -$2.92 million | Fiscal year 2015: -$7.23 million | Fiscal year 2014: -$5.03 million | Fiscal year 2013: -$1.05 million | Fiscal year 2012: -$995.0 thousand | Fiscal year 2011: -$3.42 million | Fiscal year 2010: -$400.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: